Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;41(2):335-343.
doi: 10.14366/usg.21099. Epub 2021 Sep 30.

Hyperechoic pancreas on ultrasonography: an analysis of its severity and clinical implications

Hyunji Oh  1 , Hyun Jeong Park  1 , Jiyun Oh  1 , Eun Sun Lee  1 , Sung Bin Park  1 , Min Jae Cha  2 , Soohyun Ahn  2
Affiliations

Hyperechoic pancreas on ultrasonography: an analysis of its severity and clinical implications

Hyunji Oh et al. Ultrasonography. 2022 Apr.

Abstract

Purpose: This study investigated risk factors for hyperechoic pancreas (HP) on ultrasonography (US) according to HP severity.

Methods: Between December 2008 and February 2014, 1,459 subjects who underwent abdominal US as part of health examinations were retrospectively included. Two radiologists assessed and categorized the severity of HP as normal, mild, moderate, and severe. Subjects were allocated to two groups as follows: fatty pancreas 1 (FP1; mild to severe HP) and fatty pancreas 2 (FP2; moderate to severe HP). Clinico-metabolic parameters such as the body mass index and blood test profile of subjects with normoglycemia and prediabetes/diabetes were compared (normal vs. FP1; normal or mild HP vs. FP2). Logistic regression analysis was used to evaluate the associations between HP, nonalcoholic fatty liver disease (NAFLD), and diabetes/prediabetes with adjustment for clinico-metabolic parameters.

Results: Of the 1,459 subjects, 71.2% and 40.4% showed HP and NAFLD on US, respectively. Normoglycemia and prediabetes/diabetes were present in 74.3% and 25.7% of subjects, respectively. Univariable analysis revealed that all the clinico-metabolic parameters were significantly associated with HP (all P<0.05). In the adjusted multivariable analysis, prediabetes/diabetes, NAFLD, age, and body mass index were significantly associated with HP with the FP1 and FP2 criteria. The independent factor with the strongest association with HP was NAFLD using the FP1 criterion (odds ratio [OR], 7.93; P<0.001) and prediabetes/diabetes using the FP2 criterion (OR, 6.96; P<0.001).

Conclusion: NAFLD and prediabetes/diabetes were associated with US-diagnosed HP. Moderate to severe HP was a better predictor of prediabetes/diabetes, suggesting that evaluating HP severity may be useful in clinical practice.

Keywords: Diabetes; Fatty pancreas; Hyperechoic pancreas; Nonalcoholic fatty liver disease; Ultrasonography.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1.
Fig. 1.. Flow diagram showing the patient selection criteria and study flow.
US, ultrasonography; HBV, hepatitis B virus; HCV, hepatitis C virus.
Fig. 2.
Fig. 2.. Classification of pancreatic echogenicity on abdominal ultrasound.
The pancreas is detected in the anterior aspect of the splenic vein. A. Abdominal ultrasonography shows non-fatty pancreas; similar to the echogenicity of the liver. B. Mild degree of hyperechoic pancreas shows slightly increased echogenicity compared to the echogenicity of the liver. C. Moderate degree of hyperechoic pancreas shows definite increased echogenicity, but lower than that of retroperitoneal fat. D. Severe degree of hyperechoic pancreas shows similar to or higher than the echogenicity of retroperitoneal fat. P, pancreas; L, left hemiliver; R, retroperitoneal fat; SV, splenic vein.
See this image and copyright information in PMC

References

    1. Despres JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008;28:1039–1049. - PubMed
    1. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689. - PubMed
    1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–344. - PubMed
    1. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13:1579–1584. - PMC - PubMed
    1. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27–38. - PubMed